- Human epidermal growth factor receptor 2 (HER2) gene expression is an important predictive and prognostic biomarker in breast cancer (BC), which also guides treatment recommendations.
- The expression of HER2 is a continuum from null to positive and includes HER2-low and ultra-low as targets for anti-HER2 antibody–drug conjugates (ADC).
- However, HER2-low and ultra-low have not been studied in male BC.
- Here, we analyze whether there are any differences in molecular and immunological features between HER2-low, ultra-low and HER2-null/negative expression in males with BC.
Publications
Molecular and immunological characterization of HER2-low, HER2 ultra-low, and HER2-null male breast cancer
– Caris Life Sciences